What KVK Tech does

KVK Tech, Inc. is a privately held specialty pharmaceutical manufacturer founded in 2004 and headquartered in Newtown, Pennsylvania. The company develops, manufactures, and markets FDA-approved generic medicines across multiple dosage forms — tablets, capsules, liquids, ointments/creams, nasals, ophthalmics, and (soon) injectables — and operates one branded-generic product, Lomaira (phentermine HCl USP 8 mg), positioned as a low-cost weight-loss alternative to branded competitors such as Qsymia, Belviq XR, and Contrave. All products are manufactured, packaged, and distributed in-house in the United States, an integrated model KVK cites as a key differentiator versus competitors reliant on offshore supply. The product portfolio spans therapeutic areas including weight management, allergy, cardiovascular, ophthalmology, neurology, urology, hepatology, nephrology, and anti-infectives.

The company monetizes its portfolio primarily through wholesale distribution to the nation's largest pharmacy chains, wholesalers, and distributors, supplemented by patient assistance programs (the Lomaira 1-2-3 Savings Program at $5–$15/month and the Lo-Cost Access Program at ≤50¢ per tablet) that drive retail pull-through. KVK also pursues contract development and manufacturing services — formulation, Chemistry, Manufacturing & Controls (CMC), and FDA submission readiness — through strategic partnerships such as Sen-Jam Pharmaceutical, where it holds exclusive U.S. manufacturing rights and an equity stake. International expansion is executed via licensing agreements (e.g., Productos Medix for Lomaira in Mexico). Under its Vision 2025 initiative, KVK is constructing a 250,000-square-foot sterile injectable plant in Langhorne, PA and acquired a 461,000-square-foot former Lockheed-Martin complex adjacent to its Newtown headquarters, materially expanding capacity and signaling entry into higher-value sterile injectables.

Name

KVK Tech

Legal name

KVK Tech, Inc.

Website

https://kvktech.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

101–250 employees

Short description

KVK Tech is a privately held, Newtown, Pennsylvania-based specialty pharmaceutical manufacturer founded in 2004 that develops, manufactures, and distributes FDA-approved generic medicines and the branded-generic weight-loss product Lomaira domestically across multiple dosage forms and therapeutic areas.

Ownership category

akta.pro rank

Headquarters

HQ city

Newtown

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Others, Infrastructure

Revenue model

1. Generic Pharmaceutical Product Sales: KVK develops, manufactures, and markets FDA-approved generic pharmaceuticals, generating revenue through the sale of prescription generic medications to pharmacy chains, wholesalers, distributors, and healthcare providers. Revenue is driven by product portfolio breadth across multiple therapeutic areas and dosage forms.
2. Contract Manufacturing & Development Services: KVK provides formulation development, CMC, and FDA submission readiness services to partner companies such as Sen-Jam Pharmaceutical, including exclusive manufacturing and distribution rights for the United States, generating service and licensing fees.
3. International Licensing & Royalties: Licensing agreements with international partners such as Medix in Mexico for the manufacture, distribution, and marketing of Lomaira, generating milestone payments and ongoing royalties.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

KVK Tech is a specialty pharmaceutical company that develops, manufactures, and markets FDA-approved generic prescription medications and one branded product (Lomaira) across therapeutic areas including weight management, allergy, muscle relaxation, cardiovascular, and ophthalmology. The company operates fully integrated U.S.-based manufacturing facilities in Pennsylvania, producing oral solids (tablets, capsules), liquids, ointments/creams, nasals, ophthalmics, and injectables. It also provides formulation, CMC, and FDA submission readiness services to development partners.

Product overview

KVK Tech is a specialty pharmaceutical manufacturer offering a portfolio of FDA-approved generic drugs and one branded product (Lomaira). The company manufactures all products in-house at their Pennsylvania facility, covering oral solids (tablets, capsules), oral suspensions, ophthalmic drops, and injectable solutions. The core branded product is Lomaira, an appetite suppressant for weight reduction. The generic portfolio includes medications across therapeutic categories: weight management (phentermine, benzphetamine, phendimetrazine), allergy (chlorpheniramine, promethazine, hydroxyzine), muscle relaxants (cyclobenzaprine), cardiovascular (betaxolol, isoproterenol), neurological/psychiatric (butalbital combinations), urological (oxybutynin), hepatology (ursodiol), nephrology (sodium polystyrene sulfonate), anti-infectives (atovaquone), immunosuppression (cyclosporine), and anti-inflammatory (indomethacin). The company positions itself on quality, affordability, and domestic manufacturing.

Differentiator

Problem solved

Functional benefit

Brands

• Lomaira: FDA-approved phentermine hydrochloride USP 8mg tablets for weight reduction, the company's flagship branded generic product.

Products and services

• Lomaira (phentermine hydrochloride USP) 8mg tablets, CIV Prescription weight reduction medication containing phentermine hydrochloride, the most commonly prescribed drug for weight loss. The only strength of phentermine FDA-approved for use up to three times daily before meals, offering flexible dosing for personalized weight-loss treatment plans.
• Atovaquone Oral Suspension, USP 750 mg/5mL Prescription medication for treating Pneumocystis jiroveci pneumonia (PCP) in teenagers and adults with HIV, and for preventing immunocompromised patients from contracting this type of pneumonia.
• Betaxolol Tablets, USP Beta-blocker medication for the treatment of hypertension, equivalent to brand Kerlone.
• Cyclobenzaprine HCl, USP Muscle relaxant medication for relieving muscle spasms, equivalent to brand Flexeril.
• Cyclosporine Emulsion Ophthalmic Drops 0.05% Authorized generic version of Restasis for treating dry eye disease, providing the same formulation as the brand-name product.
• Hydroxyzine HCl Tablets Antihistamine medication for anxiety relief and allergic conditions, equivalent to brand Atarax.
• Phentermine HCl Appetite suppressant medication available in tablet and capsule forms (15mg, 30mg, 37.5mg), equivalent to brand Adipex-P and Fastin.
• Phendimetrazine Tartrate Tablets Appetite suppressant medication for short-term weight reduction, available in yellow and blue formulations, equivalent to brands Bontril PDM and Plegine.
• Benzphetamine HCl Tablets Appetite suppressant medication for weight reduction, equivalent to brand Didrex.
• Butalbital-Acetaminophen-Caffeine Tablets Combination analgesic medication for tension headaches, equivalent to brand Fioricet.
• Chlorphen-12 / Chlorpheniramine Maleate ER Tablets Extended-release antihistamine for allergy relief, equivalent to brand Chlor-Trimeton 12 Hour.
• Oxybutynin Chloride Tablets Anticholinergic medication for overactive bladder, equivalent to brand Ditropan.
• Promethazine HCl Tablets Antihistamine and anti-nausea medication, equivalent to brand Phenergan.
• Indomethacin Extended Release Capsules NSAID medication for pain, inflammation, and arthritis, equivalent to brand Indocin SR.
• Isoproterenol HCl Injection Solution Bronchodilator and cardiac stimulant injection, equivalent to brand Isuprel.
• Sodium Polystyrene Sulfonate (SPS) Potassium-binding resin medication for treating hyperkalemia, available in powder form and unit dose, equivalent to brand Kayexalate.
• Ursodiol Capsules Bile acid medication for treating gallstones and liver conditions, equivalent to brand Actigall.
• Contract Development, CMC and Manufacturing Services Pharmaceutical formulation, CMC, and FDA submission readiness services offered to development partners, including exclusive U.S. manufacturing and distribution rights, as demonstrated through the Sen-Jam Pharmaceutical agreement.

Quantifiable outcome

• Lomaira costs $43.50/month for 3 tablets/day vs. competing treatments: Qsymia ($204.18), Belviq XR ($286.60), Contrave ($264.57)
• +1 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered minor and core.

• TASK ClinicalminorOthers · 11 December 2025TASK Clinical, a global contract research organization, partnered with Sen-Jam Pharmaceutical and will fund two-thirds of the upcoming Phase 3 clinical trial for SJP-001 in exchange for equity. KVK serves as Sen-Jam's corporate venture partner on this program.
• Sen-Jam PharmaceuticalcoreStrategic or Co-development Partner · 22 March 2022Sen-Jam Pharmaceutical entered a strategic development, manufacturing, distribution, and license agreement with KVK Tech for an oral COVID-19 therapeutic. KVK provides formulation and Chemistry, Manufacturing & Controls (CMC) services while Sen-Jam completes Phase II clinical trials. KVK is making a strategic investment and will have exclusive Manufacturing and Distribution rights for the United States. KVK also serves as KVK's corporate venture partner handling formulation, CMC, and FDA submission readiness for SJP-001 (hangover-prevention therapeutic).
• Productos Medix S.A. de C.V. (Medix)coreChannel Partner/ Reseller/ Distributor · 14 November 2017KVK entered a strategic licensing agreement with Medix for the manufacture, distribution, and marketing of Lomaira (phentermine hydrochloride USP) 8mg tablets in Mexico. Medix, a leader in pharmaceutical obesity products in Mexico, plans to leverage its extensive physician network and portfolio of over 10 weight-loss products. The agreement includes milestone payments and royalties to KVK. Mexico has the second largest population with obesity in the world.

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Lannett Company: Lannett is a U.S.-based specialty generic pharmaceutical manufacturer with comparable portfolio breadth across multiple dosage forms and therapeutic categories, similar mid-market scale, and similar reliance on a broad generic portfolio for revenue.
• Endo Pharmaceuticals: Endo operates a specialty generics and branded generics business with overlapping therapeutic categories (pain, urology, ophthalmology) and a similar U.S. manufacturing footprint. Comparable in serving retail pharmacy chains and wholesalers through a generics-led model.
• Upsher-Smith Laboratories: Upsher-Smith is a privately held U.S. specialty generics manufacturer of similar size and structure, with comparable FDA-approved generic portfolio and domestic manufacturing focus — a near-direct comparability on business model.
• Amneal Pharmaceuticals: Amneal is a major U.S. generic pharmaceutical manufacturer with a broad portfolio spanning solid orals, injectables, and ophthalmics — directly comparable to KVK's dosage-form breadth and therapeutic categories.
• Camber Pharmaceuticals: Camber is a U.S. generics manufacturer specializing in oral solids and other dosage forms; was named alongside KVK in Stanford's methylphenidate quality study, indicating a directly comparable product portfolio and competitive positioning.
• Apotex Corp. Apotex is a major privately held Canadian-headquartered generic manufacturer with a significant U.S. commercial presence across solid orals and other dosage forms; comparable in business model and customer base to KVK.
• Patriot Pharmaceuticals: Patriot Pharmaceuticals is a U.S. specialty generics company; named alongside KVK-TECH in the Stanford methylphenidate quality study, indicating a directly comparable generics portfolio in the U.S. market.

Broad incumbents

• Sandoz (Novartis): Sandoz is one of the world's largest generic pharmaceutical manufacturers; identified alongside KVK in third-party quality rankings. A broader incumbent that competes across most of KVK's therapeutic categories but at vastly greater scale.
• Sun Pharmaceutical Industries: Sun Pharma is a global specialty generics leader; named alongside KVK in Stanford's methylphenidate quality study, signaling overlapping U.S. generic portfolios and directly competitive positioning.
• Teva Pharmaceutical Industries: Teva is the largest global generic manufacturer with broad U.S. presence across multiple dosage forms including sterile injectables; a broad incumbent that competes with KVK across most categories and is the dominant force shaping U.S. generic pricing dynamics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/kvktech
• LinkedInlinkedin.com/shareArticle?mini=true&url=https://kvktech.com
• Xx.com/kvktech

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KVK Tech